DALFOPRISTIN MESYLATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C34H50N4O9S.CH4O3S
Molecular Weight	786.953
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(O)(=O)=O.CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(C)=C\[C@@H](O)CC(=O)CC3=NC(=CO3)C2=O

InChI

InChIKey=ZUBXFMSQBHKVNC-ODOOVVHSSA-N

InChI=1S/C34H50N4O9S.CH4O3S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42;1-5(2,3)4/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41);1H3,(H,2,3,4)/b10-9+,12-11+,23-18+;/t24-,25-,28-,31-,32-;/m1./s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050747s014,050748s013lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9511075

Dalfopristin is a pristinamycin-like component of anti-bacterial drug called Synercid which also containes quinupristin (quinupristin:dalfopristin ratio is 30:70 (w/w)). The drug was approved by FDA and used for the treatment of skin diseases caused by Staphylococcus aureus or Streptococcus pyogenes. Dalfopristin binds to the RNA of the 50S ribosomal subunit and thus inhibits the late phase of protein synthesis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial 70S ribosome 179 Target ID: CHEMBL2363135 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050747s014,050748s013lbl.pdf	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Complicated skin and skin structure infections caused by Staphylococcus aureus or Streptococcus pyogenes 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050747s014,050748s013lbl.pdf	Curative		Approved 8429	SYNERCID Approved Use Synercid is indicated in adults for the treatment of the following infections when caused by susceptible strains of the designated microorganisms. Complicated skin and skin structure infections caused by Staphylococcus aureus (methicillin susceptible) or Streptococcus pyogenes. Launch Date 1999

C_max

Value	Dose	Co-administered	Analyte	Population
7.96 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050747s015,050748s014lbl.pdf	5.25 mg/kg bw 3 times / day steady-state, intravenous dose: 5.25 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered: QUINUPRISTIN	QUINUPRISTIN	DALFOPRISTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
10.57 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050747s015,050748s014lbl.pdf	5.25 mg/kg bw 3 times / day steady-state, intravenous dose: 5.25 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered: QUINUPRISTIN	QUINUPRISTIN	DALFOPRISTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.04 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050747s015,050748s014lbl.pdf	5.25 mg/kg bw 3 times / day steady-state, intravenous dose: 5.25 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered: QUINUPRISTIN	QUINUPRISTIN	DALFOPRISTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
5 mg/kg 3 times / day multiple, intravenous Recommended Dose: 5 mg/kg, 3 times / day Route: intravenous Route: multiple Dose: 5 mg/kg, 3 times / day Co-administed with:: QUINUPRISTIN(2.5 mg/kg, IV, Q8H15) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	unhealthy, 52.9 n = 263 Health Status: unhealthy Condition: Infection Age Group: 52.9 Sex: M+F Population Size: 263 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	Disc. AE: Arthralgia, Myalgia... AEs leading to discontinuation/dose reduction: Arthralgia (3%) Myalgia (2.6%) Nausea (1.1%) Myasthenia (0.7%) Flatulence (0.3%) Pain (0.3%) Pharyngitis (0.3%) Dysphagia (0.3%) Dizziness (0.3%) Chest pain (0.3%) Asthenia (0.3%) Rash (0.3%) Vomiting (0.3%) Anorexia (0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301

AEs

AE	Significance	Dose	Population
Anorexia	0.3% Disc. AE	5 mg/kg 3 times / day multiple, intravenous Recommended Dose: 5 mg/kg, 3 times / day Route: intravenous Route: multiple Dose: 5 mg/kg, 3 times / day Co-administed with:: QUINUPRISTIN(2.5 mg/kg, IV, Q8H15) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	unhealthy, 52.9 n = 263 Health Status: unhealthy Condition: Infection Age Group: 52.9 Sex: M+F Population Size: 263 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301
Asthenia	0.3% Disc. AE	5 mg/kg 3 times / day multiple, intravenous Recommended Dose: 5 mg/kg, 3 times / day Route: intravenous Route: multiple Dose: 5 mg/kg, 3 times / day Co-administed with:: QUINUPRISTIN(2.5 mg/kg, IV, Q8H15) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	unhealthy, 52.9 n = 263 Health Status: unhealthy Condition: Infection Age Group: 52.9 Sex: M+F Population Size: 263 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301
Chest pain	0.3% Disc. AE	5 mg/kg 3 times / day multiple, intravenous Recommended Dose: 5 mg/kg, 3 times / day Route: intravenous Route: multiple Dose: 5 mg/kg, 3 times / day Co-administed with:: QUINUPRISTIN(2.5 mg/kg, IV, Q8H15) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	unhealthy, 52.9 n = 263 Health Status: unhealthy Condition: Infection Age Group: 52.9 Sex: M+F Population Size: 263 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301
Dizziness	0.3% Disc. AE	5 mg/kg 3 times / day multiple, intravenous Recommended Dose: 5 mg/kg, 3 times / day Route: intravenous Route: multiple Dose: 5 mg/kg, 3 times / day Co-administed with:: QUINUPRISTIN(2.5 mg/kg, IV, Q8H15) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	unhealthy, 52.9 n = 263 Health Status: unhealthy Condition: Infection Age Group: 52.9 Sex: M+F Population Size: 263 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301
Dysphagia	0.3% Disc. AE	5 mg/kg 3 times / day multiple, intravenous Recommended Dose: 5 mg/kg, 3 times / day Route: intravenous Route: multiple Dose: 5 mg/kg, 3 times / day Co-administed with:: QUINUPRISTIN(2.5 mg/kg, IV, Q8H15) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	unhealthy, 52.9 n = 263 Health Status: unhealthy Condition: Infection Age Group: 52.9 Sex: M+F Population Size: 263 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301
Flatulence	0.3% Disc. AE	5 mg/kg 3 times / day multiple, intravenous Recommended Dose: 5 mg/kg, 3 times / day Route: intravenous Route: multiple Dose: 5 mg/kg, 3 times / day Co-administed with:: QUINUPRISTIN(2.5 mg/kg, IV, Q8H15) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	unhealthy, 52.9 n = 263 Health Status: unhealthy Condition: Infection Age Group: 52.9 Sex: M+F Population Size: 263 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301
Pain	0.3% Disc. AE	5 mg/kg 3 times / day multiple, intravenous Recommended Dose: 5 mg/kg, 3 times / day Route: intravenous Route: multiple Dose: 5 mg/kg, 3 times / day Co-administed with:: QUINUPRISTIN(2.5 mg/kg, IV, Q8H15) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	unhealthy, 52.9 n = 263 Health Status: unhealthy Condition: Infection Age Group: 52.9 Sex: M+F Population Size: 263 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301
Pharyngitis	0.3% Disc. AE	5 mg/kg 3 times / day multiple, intravenous Recommended Dose: 5 mg/kg, 3 times / day Route: intravenous Route: multiple Dose: 5 mg/kg, 3 times / day Co-administed with:: QUINUPRISTIN(2.5 mg/kg, IV, Q8H15) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	unhealthy, 52.9 n = 263 Health Status: unhealthy Condition: Infection Age Group: 52.9 Sex: M+F Population Size: 263 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301
Rash	0.3% Disc. AE	5 mg/kg 3 times / day multiple, intravenous Recommended Dose: 5 mg/kg, 3 times / day Route: intravenous Route: multiple Dose: 5 mg/kg, 3 times / day Co-administed with:: QUINUPRISTIN(2.5 mg/kg, IV, Q8H15) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	unhealthy, 52.9 n = 263 Health Status: unhealthy Condition: Infection Age Group: 52.9 Sex: M+F Population Size: 263 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301
Vomiting	0.3% Disc. AE	5 mg/kg 3 times / day multiple, intravenous Recommended Dose: 5 mg/kg, 3 times / day Route: intravenous Route: multiple Dose: 5 mg/kg, 3 times / day Co-administed with:: QUINUPRISTIN(2.5 mg/kg, IV, Q8H15) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	unhealthy, 52.9 n = 263 Health Status: unhealthy Condition: Infection Age Group: 52.9 Sex: M+F Population Size: 263 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301
Myasthenia	0.7% Disc. AE	5 mg/kg 3 times / day multiple, intravenous Recommended Dose: 5 mg/kg, 3 times / day Route: intravenous Route: multiple Dose: 5 mg/kg, 3 times / day Co-administed with:: QUINUPRISTIN(2.5 mg/kg, IV, Q8H15) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	unhealthy, 52.9 n = 263 Health Status: unhealthy Condition: Infection Age Group: 52.9 Sex: M+F Population Size: 263 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301
Nausea	1.1% Disc. AE	5 mg/kg 3 times / day multiple, intravenous Recommended Dose: 5 mg/kg, 3 times / day Route: intravenous Route: multiple Dose: 5 mg/kg, 3 times / day Co-administed with:: QUINUPRISTIN(2.5 mg/kg, IV, Q8H15) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	unhealthy, 52.9 n = 263 Health Status: unhealthy Condition: Infection Age Group: 52.9 Sex: M+F Population Size: 263 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301
Myalgia	2.6% Disc. AE	5 mg/kg 3 times / day multiple, intravenous Recommended Dose: 5 mg/kg, 3 times / day Route: intravenous Route: multiple Dose: 5 mg/kg, 3 times / day Co-administed with:: QUINUPRISTIN(2.5 mg/kg, IV, Q8H15) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	unhealthy, 52.9 n = 263 Health Status: unhealthy Condition: Infection Age Group: 52.9 Sex: M+F Population Size: 263 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301
Arthralgia	3% Disc. AE	5 mg/kg 3 times / day multiple, intravenous Recommended Dose: 5 mg/kg, 3 times / day Route: intravenous Route: multiple Dose: 5 mg/kg, 3 times / day Co-administed with:: QUINUPRISTIN(2.5 mg/kg, IV, Q8H15) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301	unhealthy, 52.9 n = 263 Health Status: unhealthy Condition: Infection Age Group: 52.9 Sex: M+F Population Size: 263 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf Page: Study 301

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587	inhibitor 1767	inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2C19 1478 CYP2E1 882

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050747s015,050748s014lbl.pdf#page=9 Page: 9.0	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050747s015,050748s014lbl.pdf#page=9 Page: 9.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050747s015,050748s014lbl.pdf#page=9 Page: 9.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050747s015,050748s014lbl.pdf#page=9 Page: 9.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050747s015,050748s014lbl.pdf#page=9 Page: 9.0	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050747s015,050748s014lbl.pdf#page=9 Page: 9.0	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050747s015,050748s014lbl.pdf#page=9 Page: 9.0	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY34389	https://www.001chemical.com/chem/112362-50-2
AA Blocks	AA008T0Y	https://www.aablocks.com/goods/Goods/detail?id=AA008T0Y
AbMole Bioscience	M6129	http://www.abmole.com/products/dalfopristin.html
Alfa Chemistry	112362-50-2	https://www.alfa-chemistry.com/cas_112362-50-2.htm
Ambeed	A271356	https://www.ambeed.com/products/112362-50-2.html
BLD Pharm	BD123362	http://www.bldpharm.com/products/112362-50-2.html
BenchChem	B524967	https://www.benchchem.com/product/b524967
BioChemPartner	BCP22325	http://www.biochempartner.com/112362-50-2-BCP22325
CSNpharm	CSN10739	https://www.csnpharm.com/products/dalfopristin.html
Chem Scene	CS-6142	http://www.chemscene.com/112362-50-2.html
Chemspace	CSSS00161189721	https://chem-space.com/CSSS00161189721
Finetech	FT-0665456	http://www.finetechnology-ind.com/prod/detail/pub/112362-50-2.html
Glentham Life Sciences	GA0156	http://www.glentham.com/products/product/GA0156/
Lab Network	LN01270720	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01270720
MedChem Express	HY-A0241	https://www.medchemexpress.com/Dalfopristin.html
MolPort	MolPort-046-702-035	https://www.molport.com/shop/molecule-link/MolPort-046-702-035
Molcore	MC34389	https://www.molcore.com/product/112362-50-2
MuseChem	I000465	https://www.musechem.com/product/I000465.html
Selleck Chemicals	S6761	http://www.selleckchem.com/products/dalfopristin.html
Smolecule	S524967	http://www.smolecule.com/products/s524967
THE BioTek	bt-266951	https://www.thebiotek.com/product/inhibitors/bt-266951
Yuhao Chemical	YH25114	http://www.chemyuhao.com/112362-50-2.html

PubMed

Title	Date	PubMed
Quinupristin-dalfopristin is active against Toxoplasma gondii.	1999 Aug	10428933

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage for the treatment of complicated skin and skin structure infections is 7.5 mg/kg q12h.

Route of Administration: Intravenous

In Vitro Use Guide

The combination of quinupristin and dalfopristin (Synercid) exhibits in vitro minimum inhibitory concentrations (MIC's) of ≤1.0 ug/mL against most (≥90%) isolates of the following microorganisms: Corynebacterium jeikeium, Staphylococcus aureus (methicillin-resistant isolates), Staphylococcus epidermidis (including methicillin-resistant isolates, Streptococcus agalactiae.

Name

Type

Language

DALFOPRISTIN MESYLATE

Common Name

English

DALFOPRISTIN MESILATE

Common Name

English

DALFOPRISTIN MESILATE [MART.]

Common Name

English

Code System Code Type Description

EVMPD

SUB36350